molecular diagnostics companies bay area

Molecular diagnostics companies bay area series#

“We look forward to supporting the parallel development of precision molecular diagnostic tests in the US and China. Assays are CFDA (Chinese FDA) and CE/IVD cleared. Assays are based on branched DNA signal amplification technology, performed without RNA purification or RT-PCR and do not require a clean room environment. The sensitivity and specificity of QClamp™ make it superior to NGS and ddPCR.ĭiaCarta’s QuantiVirus® HPV E6/E7 mRNA tests detect HPV E6/E7 mRNA in cervical and oral cancer. Mutant DNAs present at less than 0.1% can be detected.

QClamp™ mutation detection assays utilize a novel xeno-nucleic acid (XNA) clamping technology to suppress amplification of wild-type DNA allowing selective amplification of mutant DNAs in real-time PCR. Weixin Xu of BVCF will join DiaCarta board of directors.ĭiaCarta has CE/IVD assays for highly sensitive mutation detection in EGFR, KRAS, NRAS, BRAF, PIK3CA and JAK-2.

Molecular diagnostics companies bay area series#

Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. DiaCarta, Inc is a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund).